Target- |
Mechanism- |
|
Originator Org.- |
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.United States |
First Approval Date20 Dec 2013 |
|
|
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
/ Active, not recruitingNot Applicable 布地奈德福莫特罗吸入粉雾剂(II)在健康人体的生物等效性预试验
[Translation] Preliminary bioequivalence study of budesonide/formoterol inhalation powder (II) in healthy human subjects
主要研究目的
本试验旨在空腹吸入给药条件下,以药代动力学参数为终点指标,评估上海新黄河制药有限公司生产的布地奈德福莫特罗吸入粉雾剂(II)(规格:320μg/9.0μg)与AstraZeneca AB生产的布地奈德福莫特罗吸入粉雾剂(II)(信必可®都保®,规格:320μg/9.0μg)在人体内的药代动力学特征,同时考察给药方式、操作流程、采样量、采血时间及采血时间间隔等试验设计的合理性,并验证检测方法的可行性,为后续正式试验的设计与实施提供参考依据。
次要研究目的
评价空腹吸入给药条件下,上海新黄河制药有限公司生产的布地奈德福莫特罗吸入粉雾剂(II)(320μg/9.0μg)和AstraZeneca AB生产的布地奈德福莫特罗吸入粉雾剂(II)(信必可®都保®,规格:320μg/9.0μg)的安全性。
[Translation] Main Research Objectives
This study aims to evaluate the pharmacokinetic characteristics of budesonide/formoterol inhalation powder (II) (320 μg/9.0 μg) produced by Shanghai New Yellow River Pharmaceutical Co., Ltd., and budesonide/formoterol inhalation powder (II) (Symbicort® DuPont®, 320 μg/9.0 μg) produced by AstraZeneca AB, in humans under fasting inhalation administration conditions, using pharmacokinetic parameters as the endpoint. The study also examines the rationality of the experimental design, including administration method, procedure, sampling volume, blood collection time, and blood collection interval, and verifies the feasibility of the detection methods, providing a reference for the design and implementation of subsequent formal experiments.
Secondary study objective: To evaluate the safety of budesonide/formoterol inhalation powder (II) (320 μg/9.0 μg) manufactured by Shanghai New Yellow River Pharmaceutical Co., Ltd. and budesonide/formoterol inhalation powder (II) (Symbico® DuPont®, specification: 320 μg/9.0 μg) manufactured by AstraZeneca AB under fasting inhalation administration conditions.
/ CompletedNot Applicable 布地奈德福莫特罗吸入粉雾剂(II)在健康人体的生物等效性预试验
[Translation] Preliminary bioequivalence study of budesonide/formoterol inhalation powder (II) in healthy human subjects
本试验旨在空腹吸入给药条件下,以药代动力学参数为终点指标,评估上海新黄河制药有限公司生产的布地奈德福莫特罗吸入粉雾剂(II)(规格:320μg/9.0μg)与AstraZeneca AB生产的布地奈德福莫特罗吸入粉雾剂(II)(信必可®都保®,规格:320μg/9.0μg)在人体内的药代动力学特征,考察给药方式与操作流程、采样量、采血时间、时间间隔等设置的合理性及检测方法的可行性,为正式试验提供参考依据。评价空腹吸入给药条件下,上海新黄河制药有限公司生产的布地奈德福莫特罗吸入粉雾剂(II)(320μg/9.0μg)和AstraZeneca AB生产的布地奈德福莫特罗吸入粉雾剂(II)(信必可®都保®,规格:320μg/9.0μg)的安全性。
[Translation] This study aims to evaluate the pharmacokinetic characteristics of budesonide/formoterol inhalation powder (II) (320 μg/9.0 μg) produced by Shanghai Xinhuanghe Pharmaceutical Co., Ltd., and budesonide/formoterol inhalation powder (II) (Symbicort® DuPont®, 320 μg/9.0 μg) produced by AstraZeneca AB, under fasting inhalation administration conditions, using pharmacokinetic parameters as the endpoint. The study examines the rationality of the administration method and procedure, sampling volume, blood collection time, time interval, and the feasibility of the detection methods, providing a reference for formal trials. The safety of budesonide/formoterol inhalation powder (II) (320 μg/9.0 μg) produced by Shanghai Xinhuanghe Pharmaceutical Co., Ltd. and budesonide/formoterol inhalation powder (II) (Symbicort® DuPont®, 320 μg/9.0 μg) produced by AstraZeneca AB, under fasting inhalation administration conditions, will also be evaluated.
/ CompletedNot Applicable 布地奈德福莫特罗吸入粉雾剂(II)在健康人体的生物等效性预试验
[Translation] Preliminary bioequivalence study of budesonide/formoterol inhalation powder (II) in healthy human subjects
本试验旨在空腹吸入给药条件下,以药代动力学参数为终点指标,评估上海新黄河制药有限公司生产的布地奈德福莫特罗吸入粉雾剂(II)(规格:320μg/9.0μg)与AstraZeneca AB生产的布地奈德福莫特罗吸入粉雾剂(II)(信必可®都保®,规格:320μg/9.0μg)在人体内的药代动力学特征,考察给药方式与操作流程、采样量、采血时间、时间间隔等设置的合理性及检测方法的可行性,为正式试验提供参考依据。
评价空腹吸入给药条件下,上海新黄河制药有限公司生产的布地奈德福莫特罗吸入粉雾剂(II)(320μg/9.0μg)和AstraZeneca AB生产的布地奈德福莫特罗吸入粉雾剂(II)(信必可®都保®,规格:320μg/9.0μg)的安全性。
[Translation] This study aims to evaluate the pharmacokinetic characteristics of budesonide/formoterol inhalation powder (II) (320 μg/9.0 μg) manufactured by Shanghai Xinhuanghe Pharmaceutical Co., Ltd., and budesonide/formoterol inhalation powder (II) (Symbicort® DuPont®, 320 μg/9.0 μg) manufactured by AstraZeneca AB, under fasting inhalation administration conditions, using pharmacokinetic parameters as the endpoint. It examines the rationality of the administration route and procedure, sampling volume, blood collection time, time interval, and the feasibility of the detection methods, providing a reference for formal trials.
This study also evaluates the safety of budesonide/formoterol inhalation powder (II) (320 μg/9.0 μg) manufactured by Shanghai Xinhuanghe Pharmaceutical Co., Ltd., and budesonide/formoterol inhalation powder (II) (Symbicort® DuPont®, 320 μg/9.0 μg) manufactured by AstraZeneca AB, under fasting inhalation administration conditions.
100 Clinical Results associated with Shanghai New Yellow River Pharmaceutical Co Ltd.
0 Patents (Medical) associated with Shanghai New Yellow River Pharmaceutical Co Ltd.
100 Deals associated with Shanghai New Yellow River Pharmaceutical Co Ltd.
100 Translational Medicine associated with Shanghai New Yellow River Pharmaceutical Co Ltd.